CCL28-induced RARβ expression inhibits oral squamous cell carcinoma bone invasion

Junhee Park¹,²,³, Xianglan Zhang⁴,⁵, Sun Kyoung Lee²,³, Na-Young Song¹,²,³, Seung Hwa Son⁴, Ki Rim Kim⁶, Jae Hoon Shim², Kwang-Kyun Park¹,²,³, and Won-Yoon Chung¹,²,³,⁴,*

¹Department of Dentistry, The Graduate School, Yonsei University, Seoul 03722, Republic of Korea. ²Department of Applied Life Science, The Graduate School, Yonsei University, Seoul 03722, Republic of Korea. ³Department of Oral Biology and BK21 PLUS project, Yonsei University College of Dentistry, Seoul 03722, Republic of Korea. ⁴Oral Cancer Research Institute, Yonsei University College of Dentistry, Seoul 03722, Republic of Korea. ⁵Department of Pathology, Yanbian University Hospital, Yanji city, Jilin province, 133000, China. ⁶Department of Dental Hygiene, College of Science and Engineering, Kyungpook National University, Sangju, 37224, Republic of Korea.

Corresponding author: Won-Yoon Chung, Professor. Department of Oral Biology, College of Dentistry, Yonsei University, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Republic of Korea

Tel.: +82-2-2228-3057, Fax: +82-2-364-7113, E-mail: wychung@yuhs.ac

Conflict of interest: The authors have declared that no conflict of interest exists.
Abstract

Oral squamous cell carcinoma (OSCC) frequently invades the maxillary or mandibular bone, and this bone invasion is closely associated with poor prognosis and survival. Here, we show that CCL28 functions as a negative regulator of OSCC bone invasion. CCL28 inhibited invasion and epithelial-mesenchymal transition (EMT), and its inhibition of EMT was characterized by induced E-cadherin expression and reduced nuclear localization of β-catenin in OSCC cells with detectable RUNX3 expression levels. CCL28 signaling via CCR10 increased retinoic acid receptor (RAR)β expression by reducing the interaction between RARα and HDAC1. In addition, CCL28 reduced RANKL production in OSCC and osteoblastic cells and blocked RANKL-induced osteoclastogenesis in osteoclast precursors. Intraperitoneally administered CCL28 inhibited tumor growth and osteolysis in mouse calvaria and tibia inoculated with OSCC cells. RARβ expression was also increased in tumor tissues. In OSCC patients, low CCL28, CCR10, and RARβ expression levels were highly correlated with bone invasion. OSCC patients with higher expression of CCL28, CCR10, or RARβ had significantly better overall survival. These findings suggest that CCL28, CCR10, and RARβ are useful markers for the prediction and treatment of OSCC bone invasion. Furthermore, CCL28 upregulation in OSCC cells or CCL28 treatment can be a therapeutic strategy for OSCC bone invasion.

Key words

Oral squamous cell carcinoma, CCL28, CCR10, RARβ, Epithelial-to-mesenchymal transition, Osteolysis
Introduction

Oral squamous cell carcinoma (OSCC), which accounts for 40% of all head and neck squamous cell carcinoma (HNSCC) cases, not only frequently metastasizes to distant sites but also invades the maxillary or mandibular bone based on its anatomically close proximity to the jaw bone (1, 2). Bone invasion is a frequent complication of OSCC and dramatically impacts patient recovery and quality of life by causing high recurrence, significant morbidity, and poor prognosis (3, 4). Therefore, more accurate prediction and early detection of bone invasion in OSCC patients is required for planning appropriate treatment and disease control.

Bone invasion of cancer cells, including OSCC cells, produces severe osteolytic lesions due to interactions between the tumor and the bone microenvironment or stromal cells at the invasive front (5). OSCC cells close to the bone surface invade bones via epithelial-mesenchymal transition (EMT) and by degrading the bone matrix with proteolytic enzymes. The invading tumor cells change the bone microenvironment by secreting TNF-α, interleukins, parathyroid hormone-related protein (PTHrP), and chemokines, which activate osteoclasts directly and/or stimulate RANKL expression in stromal stem cells and osteoblasts (6, 7). The resorption of bone matrix by mature osteoclasts releases bone-storing growth factors. In particular, TGF-β has been reported to stimulate the production of osteolytic factors and invasion to jaw bone by promoting EMT in OSCC cells (8-10).

Chemokines are soluble factors secreted from various cell types in response to cytokines and growth factors and control autocrine and paracrine communications via their receptors. Most chemokines secreted by tumors and surrounding stromal cells at primary tumor sites or premetastatic niches have been recognized to contribute to the survival, acquisition of invasive phenotypes, and metastatic tropism of tumor cells (11-13). Several chemokines derived from bone-tropic tumor cells act as osteolytic factors by inducing bone resorption of osteoclasts and promoting the recruitment and differentiation of
osteoclast precursors (14-16), and the levels of these chemokines in serum or bone marrow are associated with cancer-mediated osteolysis in humans (17, 18). In the case of OSCC, various chemokines, including CXCL12/CXCR4, CCL5/CCR5, CXCL8, and CCL2, are known to play critical roles in invasion and metastasis by promoting EMT, MMP expression, and cell dissemination (19-21). OSCC cell-derived CXCL2 and CXCL13 induce RANKL expression in osteoblastic/stromal cells (22, 23), and serum levels of CXCL9 and tissue expression of CCL2 are positively correlated with OSCC bone invasion (24, 25). However, more studies are required to identify chemokines to determine the bone invasive potential of OSCC and targeted therapy for bone invasion in OSCC.

We previously reported the distinct roles of RUNX3 expression in bone destruction caused by different types of cancer. RUNX3 inhibited lung cancer cell-mediated bone destruction and blocked cancer cell invasion and osteoclastogenesis by downregulating CCL5 and upregulating CCL19 and CXCL11 (26). In contrast, RUNX3 promoted bone invasion of OSCC cells by inducing EMT and PTHrP expression (27). In the present study, we found that CCL28 is regulated by RUNX3. CCL28 inhibited the invasiveness of OSCC cells by inducing retinoic acid receptor (RAR)β via its receptor CCR10 and preventing RANKL expression in OSCC and osteoblastic cells and RANKL-induced differentiation of osteoclast precursors. We further evaluated whether the CCL28/CCR10/RARβ axis is involved in bone invasion using murine models and tumor tissues of OSCC patients. This is the first report verifying the role of CCL28 in cancer cell-mediated bone destruction.

Results

CCL28 treatment inhibits invasion and EMT in OSCC cells

To identify novel markers driving bone invasion of OSCC cells, using RT² Profiler PCR Arrays, we first investigated chemokines regulated by RUNX3, proven to play a critical role in bone invasion of OSCC in our previous study (27). Among 89 chemokines, CCL28 mRNA expression was significantly
upregulated in RUNX3 knockdown Ca9.22 gingival SCC cells (Supplemental Table 1). Increased CCL28 protein levels were also confirmed in RUNX3 knockdown Ca9.22 and YD10B OSCC cells (Supplemental Figure 1A) and in the tumor tissues of RUNX3 knockdown Ca9.22 cell-injected mice obtained from our previous study (Supplemental Figure 1B). Our finding that CCL28 expression is regulated by RUNX3 was further verified by the downregulated CCL28 expression in OSCC cells with increased RUNX3 expression (Supplemental Figure 1C). The expression of CCL28 and its receptors, CCR3 and CCR10 (Supplemental Figure 2A), and the secretion of CCL28 (Supplemental Figure 2B) were detected in RUNX3-expressing Ca9.22 and YD10B and RUNX3-nonexpressing HSC2 and HSC3 OSCC cells. However, CCL28 treatment did not affect cell viability (Supplemental Figure 2C) and induce apoptotic and necrotic cell death (Supplemental Figure 2D) in OSCC cell lines. Interestingly, the invasion of Ca9.22 and YD10B cells was markedly inhibited by CCL28 treatment in the absence or presence of TGF-β, one of the abundantly stored growth factors in the bone matrix that is released by osteoclastic bone resorption (Figure 1A), whereas the invasion of RUNX3-nonexpressing HSC-2 and HSC-3 cells was not (Supplemental Figure 3A). In addition, CCL28 treatment inhibited the invasion promoted by RUNX3 overexpression in RUNX3-expressing Ca9.22 and YD10B cells but did not inhibit the invasion promoted by RUNX3 expression in RUNX3-nonexpressing HSC-2 and HSC-3 cells (Supplemental Figure 3B). In chicken chorioallantoic membrane (CAM) invasion assays using fluorescently labeled OSCC cells, CCL28 treatment reduced the number of Ca9.22 and YD10B cells invading below the CAM surface in the absence or presence of TGF-β (Figure 1B).

EMT is a developmental process that promotes the switching of tumor cells from an epithelial phenotype to a mesenchymal phenotype with invasive properties (28). Loss of E-cadherin and accumulation of β-catenin in the nucleus are considered fundamental hallmarks of EMT. TGF-β, a typical EMT inducer in cancer cells, reduces E-cadherin expression required for cell-cell adhesion and stimulates the nuclear localization of β-catenin for the transcription of EMT-related target genes (29, 30). Confocal imaging (Figure 1C) and Western blot analysis (Figure 1D) indicated that CCL28 treatment increased E-cadherin expression and blocked the downregulation of E-cadherin by TGF-β.
stimulation in Ca9.22 and YD10B OSCC cells. Furthermore, CCL28 treatment downregulated EMT-related transcription factors, Slug, Twist, and/or Snail (Figure 1D) and inhibited the translocation of β-catenin from the cytoplasm to the nucleus (Figure 1E) in both OSCC cell lines in the absence or presence of TGF-β. These results indicate that CCL28 expression is downregulated by RUNX3 in RUNX3-expressing OSCC cells, although CCL28 is expressed in all OSCC cells, and that CCL28 treatment inhibits cell invasion and EMT in RUNX3-expressing OSCC cells.

The CCL28/CCR10 axis inhibits OSCC cell invasion and is associated with oral carcinogenesis

Next, we investigated whether the blockade of CCL28 expression in Ca9.22 and YD10B OSCC cells could affect their invasion. Invasion was noticeably enhanced in Ca9.22 and YD10B cell lines transduced with CCL28-specific shRNAs compared with that in control cells transduced with corresponding nonspecific scrambled shRNAs but was inhibited by CCL28 treatment (Figure 2A). CCL28 is known as a functional ligand for CCR3 and CCR10 (31). We established CCR3 or CCR10 knockdown cells using Ca9.22 and YD10B OSCC cell lines and specific shRNA-containing lentiviral particles. OSCC cell invasion was not affected by CCR3 (Figure 2B) or CCR10 knockdown (Figure 2C). CCL28 treatment did not inhibit the invasion of CCR10 knockdown OSCC cells but still inhibited that of CCR3 knockdown cells. The results of CAM invasion assays supported the in vitro effect of CCL28 or CCR10 knockdown on the invasion of OSCC cells in the absence or presence of CCL28 (Figure 2D). These results suggest that the reduced CCL28 expression promotes the invasion of Ca9.22 and YD10B OSCC cells and that the release of CCL28 into the tumor microenvironment from OSCC cells and surrounding stromal cells can transmit the CCL28 signal into OSCC cells via CCR10, thereby inhibiting the invasion of Ca9.22 and YD10B OSCC cells.

Clinical data from The Cancer Genome Atlas (TCGA) database showed that compared to that in adjacent normal tissues, CCL28 gene expression was significantly downregulated in HNSCC tissues, whereas the gene expression of its receptors CCR3 and CCR10 was not significantly different (Figure
Additionally, the overall survival of HNSCC patients with higher gene expression of CCL28 or CCR10, but not CCR3, was increased (Figure 2F). These results indicate that CCL28 and CCR10 are associated with carcinogenesis and prognosis in HNSCC patients.

**CCL28 inhibits OSCC cell invasion by stimulating retinoic acid response element (RARE)-related transcriptional activity via CCR10 and upregulated RARβ expression**

To determine the molecular mechanism underlying the anti-invasive activity of CCL28 via CCR10, we measured the activities of 45 pathways in Ca9.22 and YD10B OSCC cells and their CCR10 knockdown counterparts using Signal Finder Reporter Arrays and described the expression levels of reporter genes as fold changes in CCL28-treated OSCC cells versus CCL28-untreated cells and in CCL28-treated CCR10 knockdown cells versus CCL28-untreated CCR10 knockdown cells. Interestingly, the expression of the reporter gene associated with RAREs was enhanced by CCL28 treatment in Ca9.22 and YD10B cells but not by CCL28 treatment in CCR10 knockdown OSCC cells (Figure 3A). In the presence of endogenous retinoic acid (RA), the binding of RAR/retinoid X receptor (RXR) heterodimers to RAREs mediates the transcription of primary RA target genes, including *RARB*. RARβ, particularly its isoform RARβ2, has been shown to suppress tumors by inducing cell cycle arrest, differentiation, and apoptosis, and the silencing of RARβ and RARβ2 has been correlated with tumor grade in human cancers (32, 33). Analysis of TCGA HNSCC dataset showed that CCL28 gene expression was significantly correlated with the expression of the RARβ gene and the RA signature corresponding to the sum of expression values of the genes that are regulated by agonists of RARs (Figure 3B). We confirmed that CCL28 treatment upregulated RARβ and RARβ2 protein expression in Ca9.22 and YD10B OSCC cells but not in HSC2 and HSC3 cells (Figure 3C). RARβ and RARβ2 protein expression was upregulated in CCL28-overexpressing Ca9.22 and YD10B OSCC cells and downregulated in CCL28-knockdown cells (Figure 3D). The upregulation of RARβ by CCL28 treatment was abrogated by CCR10 knockdown but not by CCR3 knockdown (Figure 3D). Treatment with the RARβ-selective antagonist LE135 or the inverse pan-RAR agonist BMS493 blocked CCL28-
mediated inhibition of invasion in Ca9.22 and YD10B OSCC cells (Figure 3F). These results indicate that CCL28/CCR10 signaling inhibits OSCC cell invasion by inducing RARβ, particularly RARβ2, expression via RARE-related transcriptional activation.

**CCL28 induces RARβ expression by decreasing RARα-HDAC1 interaction**

Upon the binding of ligands, RARα controls the expression of RARβ at the transcriptional level (34). Thus, we determined whether RARβ expression could also be regulated by RARα in CCL28-treated Ca9.22 and YD10B OSCC cells. The protein level of RARα was elevated by CCL28 treatment as observed for RARβ and RARβ2. Treatment with a selective RARα antagonist ER50891 blocked the upregulation of RARβ and its isoform RARβ2 in CCL28-treated OSCC cells (Figure 4A) and abrogated the inhibitory effect of CCL28 on OSCC cell invasion (Figure 4B). In addition, treatment with ER50891 or LE135 blocked the upregulation of E-cadherin and rescued the expression of EMT-related transcription factors as well as the nuclear translocation of β-catenin in CCL28-treated OSCC cells (Supplemental Figure 4). The expression of tumor suppressor genes, including *RARB*, is often inactivated by the methylation of upstream promoter regions of target genes and chromatin deacetylation in tumor cells (35). The *RARB2* promoter is methylated in two-thirds of head and neck cancers and half of oral intraepithelial neoplasia cases. In head and neck cancer cell lines with the unmethylated *RARB2* promoter, *RARB2* silencing has been suggested to be involved in histone deacetylation (36). DNA methyltransferase (DNMT) and histone deacetylase (HDAC) are recruited to the transcriptional corepressor complex interacting with RARα on RAREs, blocking the expression of RARβ at the transcriptional level. In addition, DNMT and HDAC inhibitors have been shown to reactivate RARβ (37). Based on Western blotting and IP assays, CCL28 treatment decreased the interaction between RARα and HDAC1 but not the interaction between RARα and DNMT (Figure 4C). We further investigated the acetylation of histone H3 and recruited HDAC1 levels in the RARβ promoter region of CCL28-treated OSCC cells by ChIP-qPCR. Acetylated histone H3 levels were
increased and HDAC1 levels were decreased by CCL28 treatment (Figure 4D). These results suggest that CCL28 upregulates RAR\(\alpha\)-mediated transcription of RAR\(\beta\) by reducing HDAC1-induced epigenetic changes, thereby inhibiting EMT and invasion in OSCC cells.

**CCL28 inhibits RANKL expression in OSCC and osteoblastic cells and RANKL-induced differentiation in osteoclast precursors**

Cancer cells causing bone loss directly secrete RANKL or stimulate RANKL production in osteoblastic/stromal cells exposed to cancer cell-derived osteolytic factors. RANKL induces osteoclastogenesis by binding to its receptor RANK on osteoclast precursors, and the differentiated osteoclasts participate in bone resorption. RANKL is counteracted by its decoy receptor osteoprotegerin (OPG). Treatment with OPG inhibits bone invasion of OSCC cells by inhibiting osteoclastogenesis and cancer cell migration (38). CCL28 treatment significantly reduced the secreted levels of RANKL from Ca9.22 and YD10B OSCC cells but did not affect those of OPG, lowering the RANKL/OPG ratio (Figure 5A). These effects of CCL28 were not detected in HSC2 or HSC3 OSCC cells (Supplemental Figure 5A). Treatment with the selective RAR\(\alpha\) antagonist ER50891 and the RAR\(\beta\) antagonist LE135 prevented the reduction in RANKL levels secreted from CCL28-treated Ca9.22 and YD10B OSCC cells (Figure 5B). In the absence of OSCC cell-conditioned media containing osteolytic factors, CCL28 treatment reduced RANKL levels but did not affect OPG levels secreted from hFOB1.19 osteoblastic cells (Figure 5C). Treatment with OSCC cell-conditioned media elevated the secreted levels of RANKL and lowered those of OPG in osteoblastic cells. However, CCL28 treatment significantly restored the RANKL/OPG ratio by blocking elevated RANKL production (Figure 5D). In addition, CCL28 treatment inhibited RANKL-induced osteoclast formation in bone marrow-derived macrophages (BMMs) as osteoclast precursors (Figure 5E). In RANKL-treated BMMs, osteoclast formation was inhibited by conditioned media of CCL28-overexpressing OSCC cells but increased by conditioned media of CCL28-knockdown OSCC cells (Supplemental Figure 5B). These results indicate that CCL28 inhibits osteoclast formation by decreasing RANKL levels in both OSCC cells and osteoblasts, as well
as by directly affecting RANKL-stimulated osteoclast precursors.

**CCL28 treatment inhibits OSCC-induced osteolysis in vivo**

We further evaluated the in vivo activity of CCL28 using two murine models of cancer cell-mediated bone loss, calvarial and intratibial xenograft mouse models. In the calvarial model, subcutaneously injected cancer cells directly invade the calvarium by penetrating the basement membrane and induce osteolysis (39). Ca9.22 OSCC cells were inoculated in the calvaria of mice, and CCL28 was intraperitoneally injected three times per week. Indeed, tumor volume was suppressed by CCL28 administration in a dose-dependent manner and almost completely at 50 μg/kg (Figure 6A). Three-dimensional (3D) imaging (Figure 6B) and evaluation of bone volume over total volume (BV/TV) and bone surface density (BS/BV), which are bone morphometric parameters derived from μCT scans (Figure 6C), showed that OSCC-induced osteolysis was significantly inhibited by CCL28 injection. Intraperitoneal administration of CCL28 at 50 μg/kg blocked the decrease in BV/TV and the increase in BS/BV by OSCC cell inoculation. CCL28 administration inhibited the serum levels of bone turnover markers, including calcium, tartrate-resistant acid phosphatase (TRAP) 5b, C-terminal cross-linking telopeptide of type I collagen (CTX), and alkaline phosphatase (ALP), in OSCC cell-inoculated mice (Figure 6D). H&E staining also showed that CCL28 administration inhibited tumor growth and bone invasion (Figure 6E). TRAP staining indicated a reduced number of TRAP-positive osteoclasts at the invasive front of the tumor in CCL28-treated mice compared with that in vehicle-treated mice (Figure 6E and 6F). IHC analysis showed that CCL28 administration suppressed the expression of Ki67, a proliferation marker, and CD31, an endothelial cell marker, but induced the expression of RARβ (Figure 6G).

Moreover, the increased CCL28 expression in OSCC cells reduced the invasive capability of cancer cells (Supplemental Figure 6A) and mitigated osteolysis in vivo. Compared to mice inoculated with cells with empty vector, mice inoculated with CCL28-overexpressing Ca9.22 cells exhibited reduced
tumor volume and osteolysis (Supplemental Figure 6B and C), and bone morphometric parameters, BV/TV and BS/BV, were recovered to control levels (Supplemental Figure 6D).

Oral cancer can metastasize to distant bone and induce osteolysis (1, 2). Thus, we evaluated OSCC-associated bone destruction and the effect of CCL28 injection using an intratibial xenograft model. Intraperitoneally administered CCL28 inhibited the emergence of osteolytic lesions in a dose-dependent manner by YD10B OSCC cells injected into the tibial bone marrow of mice, as shown in 3D images (Figure 7A). Moreover, CCL28 administration rescued bone morphometric parameters by significantly inhibiting the decrease in BV/TV and trabecular number (Tb.N) values and increase in trabecular separation (Tb.Sp) and the structure model index (SMI) values mediated by OSCC cell inoculation (Figure 7B). CCL28 administration also inhibited the serum levels of bone turnover markers (Figure 7C), tumor volume and bone invasion (Figure 7D and 7E), the number of TRAP-positive osteoclasts on the bone surfaces near the tumors (Figure 7D and 7F), and the expression of Ki67 and CD31 (Figure 7G) but induced RARβ expression. These findings demonstrate that CCL28 prevents tumor growth and osteolysis and upregulates RARβ in vivo.

Expression levels of CCL28, CCR10, and RARβ are closely associated with bone invasion and overall survival in OSCC patients

Next, we estimated whether CCL28, CCR3, CCR10, and RARβ can serve as critical markers for OSCC bone invasion. The expression of these proteins was detected in 117 human OSCC tissues by IHC staining using specific antibodies (Figure 8A). The histoscores for the expression of CCL28, its receptors, and RARβ ranged from 1 to 100 in most normal oral mucosa, but the expression of these molecules fluctuated in oral cancer tissues (Figure 8B). Based on the histoscores, the expression of each molecule was graded as low (histoscore 0–100) or high (histoscore 101–300). CCL28 expression showed a close correlation with RARβ expression (Supplemental Table 2). The relationships between the expression of CCL28, its receptors, or RARβ and clinicopathologic characteristics in OSCC patients
are displayed in Table 1. Bone invasion was detected in 57.3% of 117 OSCC patients and at a higher frequency than perineural and vascular invasion. Low CCL28, CCR10, and RARβ expression levels were highly correlated with bone invasion in OSCC patients. In addition, OSCC patients with higher expression of CCL28, CCR10, or RARβ had significantly better overall survival, but the CCR3 expression level did not affect overall survival (Figure 8C). When CCL28, CCR3, CCR10, or RARβ expression was also categorized as low or high according to the median value of histoscore, high CCL28, CCR10, or RARβ expression was associated with a prolonged overall survival (Supplemental Figure 7). These results indicate that the possibility of bone invasion is higher in OSCC patients with lower levels of CCL28, CCR10, or RARβ, leading to a poor prognosis.

**Discussion**

OSCC patients with similar T stage tumors based on tumor size can have substantially different prognoses based on the presence of bone invasion. Patients with medullary invasion of the mandible suffer from distant metastases and locoregional recurrence (4, 40). Bone invasion in OSCC patients is well recognized to predict poor prognosis, but the markers for the early diagnosis and prognostic prediction of OSCC bone invasion remain largely unknown. We previously reported the oncogenic function of RUNX3 in OSCC bone invasion, although its role in OSCC is still controversial (27, 41). Here, we delineate the epigenetic mechanism by which CCL28 inhibits bone invasion of OSCC cells and subsequent osteolysis and its potential as a predictive and prognostic indicator for OSCC bone invasion.

OSCC bone invasion and osteolysis are triggered by factors expressed or secreted by cancer cells and are amplified through interactions among cancer cells, osteoblasts, and osteoclasts (5, 7). For OSCC, a poorer prognosis was reported in patients with more than 50% of podoplanin-positive tumor cells than in other patients (42). Insulin-like growth factor-II mRNA-binding protein-3 or podoplanin expression
was correlated with T stage, lymph node metastasis, and overall survival in OSCC patients; additionally, the combined expression of these proteins was associated with bone invasion (43). Gingival SCC patients with strong expression of VEGF displayed more aggressive bone invasion (44). Higher serum levels of CXCL9, cytokeratin 19 fragment, and C-reactive proteins have also been detected in OSCC patients with bone invasion (24, 45). OSCC-derived chemokines have been mainly reported to promote bone invasion by increasing the invasive capacity of cancer cells (9, 25, 46). In this study, we found that CCL28 was downregulated by RUNX3 in Ca9.22 and YD10B OSCC cells. CCL28 inhibited the invasion of two OSCC cell lines expressing RUNX3 although indirect contributions of phenotypes, such as cell cycle arrest or apoptosis-unrelated forms of cell death, to the anti-invasive effect of CCL28 could not be fully excluded. Furthermore, CCL28 gene expression was downregulated in tumor tissues of HNSCC patients and correlated with overall survival, as shown by TCGA HNSCC dataset analysis. These findings suggest that RUNX3-expressing OSCC cells, but not all OSCC cells, are responsive to the anti-invasive activity of CCL28. CCL28 gene expression levels may be associated with the progression of HNSCC, including oral cancer.

CCL28 is constitutively produced by epithelial cells of various mucosal tissues and contributes to the regulation of host mucosal defense under physiological conditions and during infection or inflammation. The role of CCL28 in human cancer is controversial. CCL28 protein levels in patients with colon and breast tumors and CCL28 mRNA and protein levels in pleomorphic adenomas and adenolymphoma of human salivary glands were significantly lower than in paired normal tissues (47-49). A reduction in CCL28 production in colon tumors was suggested to promote tumor progression by impairing the migration of IgA-secreting cells, which mediate tumor-specific cytotoxicity through NK cells or PMN phagocytes, into tumors (50). The induction of CCL28 in tumor cells was suggested to enhance cytotoxicity by attracting CCR10-expressing activated NK cells toward tumor sites (51). On the other hand, upregulated CCL28 under hypoxic conditions has been shown to promote angiogenesis via endothelial CCR3 in lung adenocarcinoma and recruitment of Tregs and tumor growth in liver and
ovarian cancer (52-54). CCL28 overexpression stimulated breast cancer growth and metastasis by
upregulating the anti-apoptotic protein Bcl-2 and suppressing β-catenin (55) and promoted esophageal
SCC cell migration (56). A recent study reported that CCL28 was a favorable prognostic factor for the
luminal-like subtype of breast cancer but a poor prognostic indicator for the triple-negative subtype (57).
Thus, the silencing or upregulation of CCL28 may be influenced by epithelial tumors of different
origins. The role of CCL28 expression and its receptors and the underlying molecular mechanisms in
epithelial tumors remain unknown. In this study, the invasion of RUNX3-expressing Ca9.22 and
YD10B OSCC cells was inhibited by CCL28 treatment and CCL28 overexpression but improved by
the knockdown of CCL28. Furthermore, CCL28 treatment inhibited EMT in CCL28-responsive
OSCC cells by upregulating E-cadherin expression levels and reducing the expression levels of EMT-
related transcription factors and nuclear β-catenin levels. Knockdown of CCL28 receptors, CCR3
and CCR10, did not affect cell invasion, but the anti-invasive effect of CCL28 was blocked in CCR10
knockdown cells. Therefore, the downregulation of CCL28 contributes to the acquisition of invasive
ability in CCL28-responsive OSCC cells. The invasion of these OSCC cells can be blocked via
CCR10 by elevating CCL28 levels in the tumor microenvironment.

We further found that CCL28 signaling via CCR10 inhibited the invasiveness of CCL28-responsive
OSCC cells by the reduced interaction between RARα and HDAC1 on RAREs and the subsequent
induction of RARβ2. Moreover, compared with those in normal cells, reduced RARβ mRNA and/or
protein levels or loss of RARβ expression has been detected in cells of various cancer types, including
breast, head and neck, and lung cancer (58, 59). Overexpression of RARβ induced growth arrest and
apoptosis in HSC4 and HO-1-N-1 oral cancer cell lines that have very low RARβ expression and
resistance to RA (60), and downregulation of RARβ blocked the growth-inhibitory effect of RA in
HNSCC cells (61). In addition, induction of RARβ increased retinoid sensitivity and suppressed EMT
in cancer cells (62-64). RARβ expression has been reported to be activated by a rapid demethylation of
its gene promoter or the removal of HDAC1 from the RARβ gene (65, 66). Our data demonstrate that
the downregulation of CCL28 in OSCC cells reduces RARβ expression, improving the invasive ability of OSCC cells. The binding of CCL28 to CCR10 may enhance RARβ expression by blocking the recruitment of HDAC1 to the transcriptional corepressor complex interacting with RARs.

The development of OSCC cell-mediated osteolytic lesions is finally caused by osteoclasts. RANKL signaling via RANK in osteoclast precursors regulates osteoclastogenesis. OSCC cell lines were found to secrete RANKL both directly and via osteoblastic/stromal cells (67). OSCC-derived chemokines, including MCP-1, CXCL8, and CXCL13, stimulated RANKL expression and RANKL-induced osteoclastogenesis (23, 25, 68). In contrast with these chemokines, CCL28 reduced the production of RANKL, and this reduced RANKL production appeared to be associated with CCL28-induced RARβ expression in CCL28-responsive OSCC cells. Moreover, CCL28 inhibited the secreted levels of RANKL in osteoblastic cells exposed to OSCC cell-derived conditioned media or not and blocked the RANKL-induced formation of active osteoclasts. Thus, CCL28 can prevent osteoclast-mediated bone loss by blocking RANKL production in OSCC cells and osteoblastic cells and RANKL-induced differentiation of osteoclast precursors.

The inhibitory effect of CCL28 on OSCC cell-mediated osteolysis was confirmed in two murine models for cancer cell bone invasion. Intraperitoneally administered CCL28 prevented osteolysis in athymic nude mice inoculated with OSCC cells. The anti-osteoclastogenic activity of CCL28 was supported by the reduced number of TRAP-positive osteoclasts detected at the interface between tumor and bone tissues. Tumor growth was also inhibited by CCL28 treatment, and the in vivo inhibitory activity of CCL28 on tumor growth may be due to a decrease in the release of bone matrix-derived growth factors by osteoclast-mediated bone resorption rather than the direct inhibition of OSCC cell viability. Increased RARβ expression was detected in the tumor tissues of CCL28-treated mice. Furthermore, we confirmed that CCL28 overexpression in OSCC cells can also reduce tumor growth and osteolysis.
These findings support the in vitro results demonstrating that CCL28 inhibits OSCC bone invasion by upregulating RARβ.

In OSCC patients, bone invasion was detected at a higher frequency than perineural and vascular invasion. This higher frequency of bone invasion may be associated with the anatomical closeness of the lesions to bone. Downregulated CCL28, CCR10, or RARβ expression was closely related to bone invasion. Therefore, CCL28, CCR10, and RARβ expression levels are useful markers for the prediction and prognosis of OSCC bone invasion. Furthermore, CCL28 treatment or CCL28 upregulation in OSCC cells may be a novel strategy for inhibiting and treating OSCC cell invasion and osteolysis. Further studies are needed to determine whether CCL28 can also prevent bone invasion and osteolysis of bone-tropic cancer cells, including breast, prostate, and lung cancer cells.

Methods

Reagents. DMEM, α-MEM, DMEM/nutrient mixture F-12 (DMEM/F-12) without phenol red, PBS, FBS, 0.25% trypsin-EDTA, Geneticin (G418), and 1% antibiotic-antimycotic mixture were purchased from Gibco BRL (Grand Island, NY). Recombinant human CCL28 and TGF-β were obtained from PeproTech (Rocky Hill, NJ). MTT, Histopaque-1083, and puromycin were purchased from Sigma-Aldrich (St. Louis, MO). Carboxyfluorescein diacetate succinimidyl ester (CFDA-SE), blasticidin S, HRP-goat anti-rabbit IgG (H+L), and Lipofectamine RNAiMAX reagent were obtained from Invitrogen (Carlsbad, CA). Matrigel was purchased from BD Biosciences (Palo Alto, CA). The selective RARβ antagonist LE135, inverse pan-RAR agonist BMS493, and the selective RARα antagonist ER50891 were purchased from Tocris (Bristol, UK). Recombinant mouse soluble RANKL and macrophage-CSF (M-CSF) were purchased from R&D Systems (Minneapolis, MN). All reagents used in this study were of analytical grade.
**Antibodies.** Anti-RUNX3 (ab40278), anti-CCL28 (ab196567), anti-CCR3 (ab32512), anti-CCR10 (ab196567), anti-RARβ (ab124701), anti-CD31 (ab28364), anti-Ki67 (ab15580), and anti-rabbit secondary antibodies (ab97051) were purchased from Abcam (Cambridge, UK). Anti-GAPDH (sc32233), anti-E-cadherin (sc8426), anti-β-catenin (sc1496R), anti-lamin A/C (sc7293), anti-CCR10 (sc365957), anti-RARα (sc551), anti-RARβ2 (sc514585), anti-RANKL (sc9073), and anti-OPG (sc71747) antibodies and control IgG (sc2027) were purchased from Santa Cruz Biotechnology. Anti-Slug (9585S), anti-Twist1 (46702S), anti-Snail (3879S), anti-HDAC1 (34589S), anti-HDAC2 (57156S), anti-HDAC3 (85057S), anti-Acetyl-Histone H3 (9649S), anti-DNMT1 (5032S), anti-Caspase-3 (9662S), anti-PARP (9542S), and anti-mouse (7076S) secondary antibodies were purchased from Cell Signaling Technology (Danvers, MA).

**Animals.** Five-week-old male BALB/c nude mice (19 ± 1 g) were purchased from Orient Bio (Seoul, Korea), and four-week-old male ICR mice (21 ± 2 g) were obtained from NARA biotech (Seoul, Korea). The mice were given free access to commercial rodent chow and tap water and housed under specific pathogen-free conditions with a relative humidity of 50 ± 5% and a 12 h light/dark cycle at 22 ± 2°C.

**Cell lines and cell culture.** Ca9.22, HSC2, and HSC3 OSCC cells were purchased from the Japanese Collection of Research Bioresources Cell Bank (Shinjuku, Japan). YD10B OSCC cells were obtained from the Department of Oral Pathology, College of Dentistry, Yonsei University (Seoul, Korea) (69). RUNX3 knockdown Ca9.22 and YD10B cells were established in our previous study (27). These cells were grown in DMEM supplemented with 10% FBS and 1% antibiotic-antimycotic mixture at 37°C in a humidified 5% CO2. The hFOB1.19 osteoblastic cells were purchased from American Type Culture Collection (Manassas, VA) and maintained at 34°C in DMEM/F12 without phenol red but containing 10% FBS, 0.3 mg/ml G418, and a 1% antibiotic-antimycotic mixture. BMMs were isolated from the tibiae of four-week-old ICR male mice using Histopaque-1083 density gradient centrifugation. BMMs were cultured in α-MEM containing 10% FBS, 30 ng/ml M-CSF, and 1% antibiotic-antimycotic mixture.
at 37˚C in a humidified atmosphere with 5% CO₂.

**PCR array of chemokines and their receptors.** Total RNA was extracted from RUNX3-expressing or RUNX3 knockdown Ca9.22 cells using an RNeasy mini kit (Qiagen, Valencia, CA). cDNA was synthesized from extracted RNA using an RT² First Strand Kit (SABiosciences, Frederick, MD). The cDNA was mixed with RT² SYBR Green/ROX qPCR Master Mix (SABiosciences), and the mixture was added into a 96-well RT² PCR Array (SABiosciences) that includes primer pairs for 84 human genes encoding chemokines and their receptors. Quantitative real-time PCR analysis was conducted using the 7300 Real-Time PCR System (Applied Biosystems) according to the manufacturer’s instructions. Changes in gene expression by RUNX3 knockdown were determined on the basis of cycle thresholds using Web-based RT² Profiler PCR Array Data Analysis Software (SABiosciences). Changes in gene expression by RUNX3 knockdown were expressed as fold changes using the comparative △△Ct method.

**Knockdown of CCL28, CCR3, or CCL10.** To establish OSCC cells with stable knockdown of CCL28, CCR3, or CCR10, the cells were infected with shRNA-containing lentiviral particles (Sigma-Aldrich). One negative control shRNA (SHC002V) and three different shRNAs (SHCLNV-NM_020279, SHCLNV-NM_016602, and SHCLNV-NM_001837) were used for each gene. OSCC cells were seeded in 60-mm dishes, and the cells were incubated with viral supernatants in the presence of 10 μg/ml polybrene (Santa Cruz Biotechnology) for 24 h. After the viral supernatants were removed, the infected cells were cultured in fresh medium containing 10% FBS for 2 days and then incubated in medium containing 10% FBS and 10 μg/ml puromycin for an additional 2 weeks. In addition, Ca9.22 and YD10B cells (3 × 10⁵ cells/well) were transfected with negative control siRNAs, CCR3-targeting siRNAs, or CCR10-targeting siRNAs (Santa Cruz Biotechnology) using Lipofectamine RNAiMAX reagent (Invitrogen) according to the manufacturer’s instructions.
Overexpression of RUNX3 or CCL28. Stable RUNX3- or CCL28-overexpressing OSCC cells were established with the lentiviral gene expression system (Lenti-CMV-GFP-2A-Puro, LVP690, LVP802266, and LVP110389) from Applied Biological Materials (ABM, Richmond, BC, Canada) according to manufacturer’s instructions.

MTT assay. OSCC cells (2 × 10^3 cells/well) were seeded in 96-well plates. OSCC cells were treated with CCL28 at the indicated concentrations for 24 h and 72 h. The cells were incubated with 20 µl of MTT (5 mg/ml) in PBS at 37°C for 4 h. The medium was removed, and the cells were lysed with 200 µl of DMSO for 30 min at 37°C. Absorbance was determined at 570 nm using a microplate reader (Bio-Rad Laboratories, Hercules, CA).

Transwell invasion assay. The invasiveness of OSCC cells was determined using a 6.5-mm transwell chamber with an 8.0-µm pore polycarbonate membrane (Corning Costar, Lowell, MA). The lower and upper surfaces of the membrane were precoated with 1 mg/ml gelatin and Matrigel (BD Biosciences, San Jose, CA), respectively. OSCC cells (5 × 10^4 cells/0.1 ml) were seeded into the upper chamber with 5% FBS-DMEM and indicated concentrations of CCL28 in the absence or presence of TGF-β (10 ng/ml), LE135, BMS493, or ER50891. The lower chamber was filled with 0.6 ml of medium containing 10% FBS and the indicated concentration of CCL28. Twenty-four hours later, the number of invaded cells was counted under a microscope as previously described (70).

Chick CAM invasion assay. OSCC cells were labeled with 10 μM CFDA-SE in prewarmed PBS at 37°C for 15 min as previously described (71). Fertilized chicken eggs were purchased from a local distributor (Seoul, Korea) and kept in a humidified incubator at 37°C for 3 days. Three ml of egg albumin was
removed with a syringe and a small window was made using sterile scissors and forceps. The window was resealed with adhesive tape, and the eggs were incubated until 11 days of chick embryo development. On day 11, CFDA-SE-labeled OSCC cells were suspended in DMEM:Matrigel (4:1) mixture. The suspended CFDA-SE-labeled OSCC cells (1 × 10^6 cells/egg) were treated with CCL28 (50 pg/ml) and/or TGF-β (10 ng/ml) and loaded onto the CAMs of fertilized eggs (n = 3). The resealed eggs were further incubated for 3 days. On day 14, the CAMs were harvested and fixed with neutralized formalin for 24 h. Images of CAM sections were obtained using a Zeiss LSM 700 confocal microscope (Zeiss Laboratories, Jena, Germany) and analyzed using ImageJ software. Cell invasion was determined by measuring the mean fluorescence of cells that had invaded into the mesoderm layer (below the CAM surface).

Immunofluorescence staining and confocal imaging. OSCC cells (5 x 10^3 cells/well) were seeded in a chamber slide and incubated in complete medium for 24 h. After treatment with CCL28 at the indicated concentrations in the absence or presence of TGFβ, ER50891, or LE135 24 h, the cells were fixed with 4% paraformaldehyde and permeabilized with Triton X-100-containing buffer. The cells were blocked with 2% goat serum in PBS and then incubated with primary antibodies at 1:200 dilutions overnight at 4°C. After washing, the cells were incubated with Alexa Fluor 488 goat anti-mouse IgG and Alexa Fluor 594 goat anti-rabbit IgG (Invitrogen) for 1 h at room temperature. The slides were mounted in Vectashield mounting medium with DAPI (Vector Laboratories, Burlingame, CA). Images were collected using a Zeiss LSM 700 confocal microscope.

Western blot analysis. OSCC cells (1 x 10^6 cells/100 mm dish) were treated with CCL28 at the indicated concentration in the absence or presence of TGFβ, ER50891, or LE135 for 24 h. Cell lysates were prepared using RIPA buffer containing a protease inhibitor cocktail (Cell Signaling Technology). The lysates were centrifuged at 22,000 g for 15 min at 4°C. Nuclear and cytosolic fractions were obtained
from OSCC cell lysates using a nuclear/cytosol fractionation kit (BioVision, Mountain View, CA) according to the manufacturer's instructions. The protein concentration of samples was determined using a BCA kit (Pierce, Rockford, IL). Protein (20 µg) was loaded onto a SDS-polyacrylamide gel and electrophoresed, and the protein in the gels was transferred to a PVDF membrane (Millipore, Danvers, MA). The membrane was blocked with 5% skim milk in Tris-buffered saline (10 mM Tris, pH 8.0 and 150 mM NaCl) with 0.1% Tween-20 (TBS-T) and then incubated with primary antibodies (1:1000) in TBS-T containing 3% BSA. The membrane was further incubated with HRP-conjugated secondary antibodies in TBS-T containing 3% skim milk for 1 h at room temperature. The targeted proteins were visualized with Amersham ECL Western Blotting Detection Reagents (GE healthcare, Little Chalfont, UK).

**TCGA Data Mining.** TCGA HNSCC dataset was generated by the TCGA Research Network. TCGA HNSCC data were obtained from The UCSC Cancer Genome Browser in August 2015 to analyze CCL28, CCR3, and CCR10 mRNA expression in head and neck cancer tissues ($n = 519$) and normal adjacent tissues ($n = 43$) and to determine the correlation of overall survival and mRNA expression levels of CCL28 or its receptors ($n = 505$). Normalized RNA sequencing data by Expectation Maximization (RSEM) values were used to generate boxplots of genes and assess the correlation of gene expression. The RA signature is determined by the sum of the expression values of genes that are known to be regulated by an agonist of the RAR as previously described (72).

**Pathway reporter array.** Pathway analysis was conducted using the Cignal Finder 45-Pathway Reporter Array (SA Biosciences) according to the manufacturer's instructions. Twenty-four hours after cells were reversely transfected, the cells were treated with 20 pg/ml CCL28 and then incubated for another 24 h. Luciferase activity was measured using the Dual-Luciferase Assay system (Promega, Madison, WI) with a luminescence microplate reader (Varioskan Flash 3001, Thermo Fisher Scientific, Waltham, MA).
Firefly luciferase was the experimental reporter, and *Renilla* luciferase was the normalizing reporter. The fold change in the activity of each signaling pathway was calculated from the normalized luciferase activities in treated versus untreated cells.

**Co-IP.** Co-IP assays were performed using the Pierce Co-IP Kit (Thermo Fisher Scientific). Briefly, OSCC cells (1 x 10^6 cells/100 mm dish) were incubated in medium containing 10% FBS for 24 h and treated with 20 pg/ml CCL28 for an additional 24 h. The cells were lysed using 500 μl of lysis buffer, and 50 μl of whole lysate was removed for SDS-PAGE as the input control. The remaining cell lysate was incubated and immunoprecipitated with 20 μg of primary antibody against RARα and 25 μl of AminoLink Plus Coupling Gel at 4°C overnight. The immune complexes were washed five times and eluted using IgG Elution Buffer. The eluted immune complexes were boiled at 95°C in SDS-sample buffer for 5 min and detected by Western blotting.

**ChIP.** ChIP assays were performed using the Simple ChIP Enzymatic Chromatin IP Kit (Cell Signaling Technology, 9002), following the manufacturer's protocol. Anti-HDAC1 and anti-Acetyl-Histone H3 (K9) antibodies were used for chromatin precipitation, while anti-Histone H3 and rabbit IgG antibodies served as positive and negative controls, respectively. All antibodies were diluted 1:50. Following DNA purification, the presence of selected DNA sequences was assessed by qPCR using the following primers: *RARB*: forward, 5′- GTTCACCAGAAAGTTCACTCGA-3′ and reverse, 5′-CAAAGAATAGACCCTCCTGCTCT-3′; *RPL30* (Cell Signaling Technology, 7014). As a loading control, the qPCR was performed directly on input DNA purified from chromatin before IP. Data are presented as the amount of DNA recovered relative to the input control.

**Preparation of conditioned media.** OSCC cells (1 x 10^5 cells/dish) were seeded in 100-mm culture dishes for 24 h. The cells were cultured in fresh medium containing 10% FBS for 24 h. The culture
media were centrifuged at 500 × g for 5 min. The supernatants were used as conditioned media for subsequent experiments.

**ELISA.** OSCC cells (2 × 10³ cells/well) were cultured for 24 or 72 h. In addition, OSCC cells were treated with CCL28 at the indicated concentrations in the absence or presence of ER50891 (1 μM) or LE135 (5μM) for 24 h. hFOB1.19 osteoblasts (5 × 10³ cells/well) were treated with CCL28 at the indicated concentrations in the absence or presence of OSCC conditioned medium for 24 h. CCL28, RANKL, or OPG levels in cell culture media were measured with commercially available kits for CCL28 (BioLegend, San Diego, CA), RANKL (EIaB, Wuhan, China), or OPG (Boster, Pleasanton, CA) according to the manufacturer’s instructions.

**Osteoclast formation.** BMMs (5 x 10⁵ cells) were treated with CCL28 at the indicated concentrations or with 30% conditioned media from CCL28-overexpressing or CCL28-knockdown OSCC cells, together with M-CSF (30 ng/ml) and RANKL (100 ng/ml) for 5 days. The medium was replaced with fresh medium every 2 days. The cells were fixed with fixative solution for 30 seconds at room temperature, and enzyme histochemistry for TRAP was performed with a commercial kit (Sigma-Aldrich) according to the manufacturer’s instructions. Multinuclear TRAP-positive cells (≥ 3 nuclei) were considered osteoclasts.

**Murine calvarial and intratibial models of cancer-associated osteolysis.** For the calvarial model, six-week-old male BALB/c nude mice were randomly divided into groups. Ca9.22 cells (1 × 10⁷ cells/100 μl of HBSS) were subcutaneously inoculated over the calvaria of mice using a 1-ml syringe with a sterile 26-gauge needle, and the control mice were injected with HBSS alone. CCL28 at the indicated doses in PBS was intraperitoneally injected. In addition, CCL28-overexpressing Ca9.22 cells or Ca9.22 cells with empty vector were subcutaneously inoculated over the calvaria of mice. Tumor volumes at
the calvaria were measured using a digital electric caliper and calculated according to the formula \((a \times b^2)/2\), where ‘a’ is the longest diameter and ‘b’ is the shortest diameter of the tumor. On day 21, blood, calvaria, and tumor were collected. For the intratibial model, six-week-old male BALB/c nude mice were anesthetized using an intraperitoneal injection of a mixture of 30 mg/kg Zoletil (Virbac Laboratories, Carros, France) and 10 mg/kg Rompun (Bayer HealthCare Korea, Seoul, Korea). YD10B cells \((1 \times 10^6\) cells per 50 µl of HBSS) were injected into the bone marrow of the right tibia of mice through the femorotibial cartilage using a Hamilton syringe with a sterile 27-gauge needle. The control mice were injected with HBSS alone. CCL28 at the indicated doses was intraperitoneally injected. On day 28, the tibiae and blood were collected.

The effect of CCL28 on OSCC bone invasion was analyzed as previously described (26, 27). The collected calvaria and tibiae were analyzed scanned with a μCT system (SkyScan 1076, SkyScan, Aartselaar, Belgium). 3D images were generated using NRecon software (SkyScan), and bone morphometric parameters, including BV/TV, BS/TV, Tb.Th, Tb.N, Tb.Sp, or SMI, were analyzed from μCT data using CTAn software (SkyScan). Serum levels of calcium were determined using the QuantiChrome Calcium assay kit (BioAssay Systems, Hayward, CA), and serum levels of TRAP 5b and CTX were measured using a mouse TRAP assay kit (Immuno Diagnostic Systems, Boldon, UK) and a RatLaps enzyme immunoassay kit (Immuno Diagnostic Systems), respectively. H&E and TRAP staining was also performed on mouse calvarial or hind limb sections. Tumor areas and osteoclast surface per bone surface (Oc.S/BS) were measured with IMT i-Solution software (version 7.3, IMT i-Solution, BC, Canada). Tumor areas were calculated as the percentage of total tumor area per tissue area. Oc.S/BS values were determined as the percentage of bone surface in contact with osteoclasts. The expression levels of PCNA, CD31, and RARβ in tumor tissues were evaluated by IHC examination with a 1:100 dilution of each primary antibody against PCNA, CD31, and RARβ.

**Immunostaining of formalin-fixed, paraffin-embedded OSCC samples.** One hundred seventeen formalin-fixed, paraffin-embedded OSCC tissues were analyzed by IHC staining using anti-rabbit
CCL28, CCR3, CCR10, or RARβ antibody. Mouse IgG or rabbit IgG (DakoCytomation, Glostrup, Denmark) was used as a negative control. The expression levels of CCL28, CCR3, CCR10, and RARβ were interpreted using a weighted histoscore method. Staining was scored by Yan Chen and Yan Peng, who were blinded to clinical data, and classified into 4 grades (range 0–3) according to the percentage of immunopositive cells and immunostaining intensity: 0 (negative), 1 (light brown), 2 (brown), or 3 (dark brown). The histoscore was then calculated as follows: final score = (0 × percentage of negative cells) + (1 × percentage of light-brown cells) + (2 × percentage of brown cells) + (3 × percentage of dark brown cells). The samples were subsequently divided into two groups according to final histoscores: low expression (histoscores from 0 through 100) and high expression (histoscores from 101 through 300).

Statistics. The results are expressed as the mean ± SEM of three independent experiments. One representative experiment from multiple experiments is shown. Two-tailed Student’s t test and one-way ANOVA with multiple comparisons test were used for comparisons between two groups and among more than three groups, respectively. The data retrieved from the TCGA website were reanalyzed to determine Pearson’s correlation coefficients (r) between CCL28 mRNA expression and RARβ mRNA expression. Kaplan-Meier survival curves were compared using the log-rank test. The $\chi^2$ test was used to evaluate the relation between CCL28, CCR3, CCR10 or RARβ expression and different clinicopathological parameters of patients. All statistical analyses were performed using SPSS version 19.0 (SPSS Inc., New York, NY). $P < 0.05$ was considered statistically significant.

Study approval. All animal experiments were approved by the IACUC of the Department of Laboratory Animal Resources, Yonsei Biomedical Research Institute, Yonsei University College of Medicine (Approval number 2013-0100-1 and 2015-0355). Human OSCC tissues were obtained from patients at the Department of Oral and Maxillofacial Surgery, Dental Hospital, Yonsei University Medical Center from 1995 to 2016, and the study was approved by the institutional review board at Yonsei University.
College of Dentistry (Approval number 2-2017-0004). All patients provided written informed consent prior to inclusion in the study.

Author contributions

WYC and JP conceived and designed the study. JP, SKL, and XZ performed experiments and data analysis. NYS, SHS, KRK, JHS, and KKP contributed to experimental design and data analysis. JP, KKP, and WYC contributed to manuscript writing. All authors revised and edited the manuscript.

Acknowledgements

We thank Chae-Eun Lee from the Oral Science Research Institute for providing technical assistance with μCT. This research was supported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (HI15C1901).

References


Figure 1. CCL28 inhibits invasion and EMT in OSCC cells. (A) Invasion of Ca9.22 and YD10B OSCC cells treated with CCL28 and/or TGF-β (mean ± SEM, n = 3). *P < 0.05 versus cells without CCL28 and TGF-β; †P < 0.05, ‡P < 0.005 versus TGF-β-only-treated cells by one-way ANOVA with multiple comparisons test. (B) Invasion of Ca9.22 and YD10B OSCC cells with CCL28 and/or TGF-β into the CAMs of fertilized eggs (mean ± SEM, n = 3). Representative images of CAM. Scale bar, 100 μm. Cells invaded into the mesoderm layer of CAMs are quantified by the mean fluorescence. *P < 0.05, **P < 0.01 versus cells without CCL28 and TGF-β; †P < 0.05, ‡P < 0.001 versus TGF-β-only-
treated cells by one-way ANOVA with multiple comparisons test. (C) Expression levels and cellular localization of E-cadherin and β-catenin in Ca9.22 and YD10B OSCC cells treated with CCL28 and/or TGF-β. Representative immunofluorescence images. Scale bar, 100 μm. (D) Expression levels of E-cadherin, β-catenin, and EMT-regulating transcription factors in Ca9.22 and YD10B OSCC cells treated with CCL28 and/or TGF-β. (E) Cytosolic and nuclear β-catenin levels in Ca9.22 and YD10B OSCC cells treated with CCL28 and/or TGF-β. (D and E) Representative Western blot images.
Figure 2. CCL28 inhibits OSCC cell invasion via CCR10 and is associated with carcinogenesis and survival in patients. (A) Invasion of CCL28 knockdown OSCC cells. (B) Invasion of CCR3 knockdown OSCC cells. (C) Invasion of CCR10 knockdown OSCC cells. (A-C) OSCC cells were transduced with lentiviral particles with control shRNAs or three different shRNAs targeting CCL28, CCR10, or CCR3. Knockdown of CCL28, CCR10, or CCR3 in transduced cells was confirmed by Western blotting (upper panels). Cell invasion is quantified as the number of invaded cells/field (mean ± SEM, n = 3). *P < 0.05, **P < 0.005 versus control shRNA-transfected cells without CCL28; ***P < 0.005 versus CCL28, CCR3, or CCR10-specific shRNA-transfected cells without CCL28 by one-way ANOVA with multiple comparisons test. (D) Invasion of CCL28 or CCR10 knockdown OSCC cells labeled with CFDA-SE and then suspended in a DMEM:Matrigel (4:1) mixture on the CAMs of fertilized eggs (mean ± SEM, n = 3). Representative images of CAM. Scale bar, 100 μm. Cells invaded into the mesoderm layer are quantified by the mean fluorescence. *P < 0.05 versus control shRNA-transfected cells without CCL28; ***P < 0.01 versus CCL28 or CCR10 knockdown cells without CCL28 by one-way ANOVA with multiple comparisons test. (E) CCL28, CCR3, or CCR10 mRNA levels in normal and HNSCC tissues. The data were obtained from the TCGA database. Box plots show the median and interquartile range. *P < 0.0001 versus normal tissue by two-tailed Student’s t test. (F) Kaplan-Meier survival curves for HNSCC patients with high or low expression of CCL28, CCR3, or CCR10 mRNA by the log-rank test.
Figure 3. The CCL28/CCR10 axis inhibits OSCC cell invasion by activating RAR signaling. (A)
Representative pathway reporter array (n = 2) for wild-type and CCR10 knockdown (KD) OSCC cells in the absence or presence of CCL28 (20 ng/ml). Reporter gene activities in CCL28-treated cells were normalized by those in untreated cells and represented as fold changes. (B) Correlations between CCL28 mRNA expression and RARβ mRNA expression in patients with HNSCC by Pearson’s correlation analysis. Scatter plots represent normalized RSEM values for each gene. (C) RARβ and RARβ2 expression in response to CCL28 treatment (20 pg/ml) in Ca9.22, YD10B, HSC2, or HSC3 OSCC cells. (D) RARβ and RARβ2 expression in CCL28-overexpressing or CCL28-knockdown Ca9.22 or YD10B OSCC cells. (E) RARβ expression in response to CCL28 treatment (20 pg/ml) in CCR3- or CCR10-downregulated Ca9.22 or YD10B OSCC cells. (C-E) Representative Western blot images. (F) Invasion of OSCC cells treated with the RARβ-selective antagonist LE135 or inverse pan-RAR agonist BMS493 in the presence of CCL28 (20 pg/ml) (mean ± SEM, n = 3). *P < 0.05, **P < 0.005 versus CCL28-untreated cells; #P < 0.05, ##P < 0.01 versus CCL28-only-treated cells by one-way ANOVA with multiple comparisons test.
Figure 4. CCL28 upregulates RARβ expression via RARα-mediated transcription by reducing the interaction between RARα and HDAC1. (A) RARβ and RARβ2 expression levels in OSCC cells treated with CCL28 (20 pg/ml) and/or the selective RARα antagonist ER50891 (ER). (B) Invasion of OSCC cells treated with CCL28 (20 pg/ml) and/or the selective RARα antagonist ER50891 (ER) (mean ± SEM, n = 3). *P < 0.001 versus CCL28-untreated control cells; #P < 0.005, ##P < 0.001 versus CCL28-only-treated cells by one-way ANOVA with multiple comparisons test. (C) Interaction between RARα and HDACs or DNMT in OSCC cells treated with CCL28 (20 pg/ml). Immune complexes were obtained using a Pierce Co-IP kit. (A and C) Representative Western blot images. (D) Acetylated histone H3 levels and HDAC1 interaction at the RARB promoter region of OSCC cells treated with CCL28 (20 pg/ml). Histone modification (H3K9ac) and HDAC1 binding were analyzed by ChIP-qPCR. Data are presented as the percentage of the total chromatin input (% input), and graphs are representative.
Figure 5. CCL28 treatment reduces the RANKL/OPG ratio in OSCC cells and osteoblasts and RANKL-induced differentiation of osteoclast precursors. (A) RANKL and OPG levels secreted by CCL28-treated OSCC cells into the culture media, and the RANKL/OPG ratio (mean ± SEM, n = 3). *P < 0.05 versus CCL28-untreated cells by two-tailed Student’s t test. (B) RANKL and OPG levels secreted by OSCC cells treated with the selective RARα antagonist ER50891 or RARβ antagonist LE135 in the presence of CCL28, and the RANKL/OPG ratio (mean ± SEM, n = 3). *P < 0.05 versus CCL28-untreated cells; #P < 0.05 versus CCL28-only-treated cells by one-way ANOVA with multiple comparisons test. (C) RANKL and OPG levels secreted by CCL28-treated osteoblasts into the culture media, and the RANKL/OPG ratio (mean ± SEM, n = 3). *P < 0.05, **P < 0.01 versus CCL28-untreated cells by one-way ANOVA with multiple comparisons test. (D) Secreted levels of RANKL and OPG by CCL28-treated osteoblasts in the presence of conditioned media (CM) from OSCC cell lines, and the RANKL/OPG ratio (mean ± SEM, n = 3). #P < 0.05, ##P < 0.01 versus control cells without CM; *P < 0.05 versus CM-only-treated cells by one-way ANOVA with multiple comparisons test. (E) Osteoclast formation in CCL28-treated BMMs in the presence of RANKL (mean ± SEM, n = 3). Representative images at ×100 magnification. *P < 0.05 versus RANKL-only-treated cells by one-way ANOVA with multiple comparisons test.
Figure 6. CCL28 treatment inhibits tumor growth and osteolysis in the calvaria of mice subcutaneously injected with OSCC cells. CCL28 was intraperitoneally administered to mice.
subcutaneously injected with Ca9.22 OSCC cells in the calvaria (n = 5 for control and n = 10 for experimental groups). (A) Tumor size (mean ± SEM). *P < 0.001 versus vehicle-treated mice by one-way ANOVA with multiple comparisons test. (B) Representative μCT 3D images of calvarial osteolytic lesions. (C) Bone morphometric parameters, BV/TV and BS/TV (mean ± SEM). (D) Serum levels of bone turnover markers (mean ± SEM). (E) Representative images of H&E and TRAP staining in calvarial tissue sections. Scale bar, 100 μm. (F) Oc.S/BS determined from TRAP staining as the percentage of bone surface in contact with osteoclasts (mean ± SEM). (C, D, and F). *P < 0.05. **P < 0.01, ###P < 0.005 versus control mice; *P < 0.05, **P < 0.01 versus OSCC cell-injected mice by one-way ANOVA with multiple comparisons test. (G) Ki67, CD31, and RARβ expression levels in calvarial tumor tissues of OSCC-injected mice. Left panel: Representative images of immunohistochemically stained tumor tissues. Scale bar, 100 μm. Graph shows quantified data. *P < 0.05, **P < 0.01 versus OSCC cell-injected mice by one-way ANOVA with multiple comparisons test.
Figure 7. CCL28 treatment inhibits tumor growth and osteolysis in mice intratibially injected with OSCC cells. CCL28 was intraperitoneally administered to mice injected with YD10B OSCC cells into the bone marrow of the right tibia (n = 5 for control and n = 7 for experimental groups). (A)
Representative μCT 3D images of osteolytic lesions in the tibia. (B) Bone morphometric parameters (mean ± SEM). (C) Serum levels of bone turnover markers (mean ± SEM). (D) Representative images of H&E and TRAP staining in tibial tissue sections. Scale bar, 100 μm. (E) Tumor area determined from H&E staining as the percentage of the total tumor area per tissue area. (F) Oc.S/BS determined from TRAP staining as the percentage of bone surface in contact with osteoclasts (mean ± SEM). (B, C, E, and F) *P < 0.05, **P < 0.01, ###P < 0.005 versus control mice; *P < 0.05, **P < 0.01 versus OSCC cell-injected mice by one-way ANOVA with multiple comparisons test. (G) Ki67, CD31, and RARβ expression levels in tibial tumor tissues of OSCC-injected mice. Left panel: Representative images of immunohistochemically stained tumor tissues. Scale bar, 100 μm. Right panel: Ki67-positive cells, CD31-positive vessels, and RARβ-positive cells were counted in tumor tissues. *P < 0.05, **P < 0.01 versus OSCC cell-injected mice by one-way ANOVA with multiple comparisons test.
Figure 8. Expression levels of CCL28, CCR10, or RARβ are closely associated with overall survival in 117 OSCC patients. (A) Representative images of IHC staining of CCL28, CCR3, CCR10, and RARβ in normal oral mucosa and OSCC tissues. Scale bar, 100 μm. Magnified images of the boxed area are shown in the insets. Scale bar, 20 μm. (B) Frequency of histoscores in normal oral mucosa and OSCC tissues. (C) Kaplan-Meier survival curve of OSCC patients stratified based on CCL28, CCR3, CCR10 or RARβ expression by the log-rank test.
Table 1. Relationships between clinicopathologic characteristics and the expression of CCL28, its receptors, or RARβ in 117 OSCC patients

<table>
<thead>
<tr>
<th></th>
<th>CCL28 histoscore</th>
<th>CCR3 histoscore</th>
<th>CCR10 histoscore</th>
<th>RARβ histoscore</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>All n = 117 (%)</td>
<td>Low (0-100) n = 92 (%)</td>
<td>High (101-300) n = 25 (%)</td>
<td>Low (0-100) n = 80 (%)</td>
</tr>
<tr>
<td><strong>Age</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt; 62</td>
<td>58(49.6)</td>
<td>34(58.6)</td>
<td>24(41.4)</td>
<td>42(72.4)</td>
</tr>
<tr>
<td>≥ 62</td>
<td>59(50.4)</td>
<td>46(78.0)</td>
<td>13(22.0)</td>
<td>50(84.7)</td>
</tr>
<tr>
<td><strong>Sex</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>78(66.7)</td>
<td>54(69.2)</td>
<td>24(30.8)</td>
<td>61(78.2)</td>
</tr>
<tr>
<td>Female</td>
<td>39(33.3)</td>
<td>26(66.7)</td>
<td>13(33.3)</td>
<td>31(79.5)</td>
</tr>
<tr>
<td><strong>Lesion site</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tongue</td>
<td>23(19.7)</td>
<td>9(39.1)</td>
<td>14(60.9)</td>
<td>16(69.6)</td>
</tr>
<tr>
<td>Floor of mouth</td>
<td>6(5.1)</td>
<td>5(83.3)</td>
<td>1(16.7)</td>
<td>4(66.7)</td>
</tr>
<tr>
<td>Retromolar trigone</td>
<td>15(12.8)</td>
<td>11(73.3)</td>
<td>4(26.7)</td>
<td>13(86.7)</td>
</tr>
<tr>
<td>Gingiva</td>
<td>62(53.0)</td>
<td>48(77.4)</td>
<td>14(22.6)</td>
<td>52(83.9)</td>
</tr>
<tr>
<td>Cheek</td>
<td>11(9.4)</td>
<td>7(63.6)</td>
<td>4(36.4)</td>
<td>7(63.6)</td>
</tr>
<tr>
<td><strong>T stage</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T1-2</td>
<td>41(36.0)</td>
<td>25(61.0)</td>
<td>16(39.0)</td>
<td>29(70.7)</td>
</tr>
<tr>
<td>T3-4</td>
<td>73(64.0)</td>
<td>54(74.0)</td>
<td>19(26.0)</td>
<td>61(83.6)</td>
</tr>
<tr>
<td><strong>N stage</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>N0</td>
<td>67(57.8)</td>
<td>44(65.7)</td>
<td>23(34.3)</td>
<td>52(77.6)</td>
</tr>
<tr>
<td>N1-3</td>
<td>49(42.2)</td>
<td>36(73.5)</td>
<td>13(31.0)</td>
<td>40(81.6)</td>
</tr>
<tr>
<td><strong>Differentiation</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Well</td>
<td>28(23.9)</td>
<td>18(64.3)</td>
<td>10(35.7)</td>
<td>21(75.0)</td>
</tr>
<tr>
<td>Moderate</td>
<td>70(59.8)</td>
<td>51(72.9)</td>
<td>19(27.1)</td>
<td>56(80.0)</td>
</tr>
<tr>
<td>Poor</td>
<td>19(16.2)</td>
<td>11(57.9)</td>
<td>8(42.1)</td>
<td>0.4</td>
</tr>
<tr>
<td>------</td>
<td>----------</td>
<td>----------</td>
<td>---------</td>
<td>-----</td>
</tr>
<tr>
<td>Perineural invasion</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>100(85.5)</td>
<td>65(65.0)</td>
<td>35(35.0)</td>
<td>77(77.0)</td>
</tr>
<tr>
<td>Yes</td>
<td>17(14.5)</td>
<td>15(88.2)</td>
<td>2(11.8)</td>
<td>0.057</td>
</tr>
<tr>
<td>Vascular invasion</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>107(91.5)</td>
<td>72(67.3)</td>
<td>35(32.7)</td>
<td>86(80.4)</td>
</tr>
<tr>
<td>Yes</td>
<td>10(8.5)</td>
<td>8(80.0)</td>
<td>2(20.0)</td>
<td>0.408</td>
</tr>
<tr>
<td>Bone invasion</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>50(42.7)</td>
<td>26(52.0)</td>
<td>24(48.0)</td>
<td>35(70.0)</td>
</tr>
<tr>
<td>Yes</td>
<td>67(57.3)</td>
<td>54(80.6)</td>
<td>13(19.4)</td>
<td>0.001</td>
</tr>
</tbody>
</table>